Last updated on February 2019

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Brief description of study

The primary objective of the study is to determine whether pemafibrate administered twice daily will delay the time to first occurrence of any component of the clinical composite endpoint of:

  • nonfatal Myocardial Infarction (MI)
  • nonfatal ischemic stroke
  • hospitalization for unstable angina requiring unplanned coronary revascularization; or
  • Cardio Vascular (CV) death.

Detailed Study Description

A multi-regional clinical trial with participating sites planned in the following countries pending approval from the applicable oversight authorities:

  • Argentina
  • Brazil
  • Bulgaria
  • Canada
  • Colombia
  • Czech Republic
  • Denmark
  • France
  • Germany
  • Hungary
  • India
  • Israel
  • Japan
  • Mexico
  • Netherlands
  • Poland
  • Romania
  • Russian Federation
  • Slovakia
  • South Africa
  • Spain
  • Ukraine
  • United Kingdom
  • United States

Clinical Study Identifier: NCT03071692

Find a site near you

Start Over

Eiseibunkakyokai Josai Hospital

Suginami-ku, Japan
  Connect »

Shinjuku Research Park Clinic

Shinjuku-ku, Japan
  Connect »

Nomura Clinic

Itabashi-ku, Japan
  Connect »

Sugiura Clinic

Kawaguchi-shi, Japan
  Connect »

Juntendo University Hospital

Bunkyo-ku, Japan
  Connect »

Tokyo Center Clinic

Chuo-ku, Japan
  Connect »

Fukuwa Clinic

Chuo-ku, Japan
  Connect »

IMS Miyoshi General Hospital

Iruma-gun, Japan
  Connect »